Histogenics pulls in $49M to support commercial development of Cartilage Repair products

By

Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products (press release)
--Proceeds to Drive Completion of Phase 3 NeoCart® Clinical Trials and EU Regulatory Clearance of VeriCart™--
Regenerative medicine company Histogenics Corporation, announced today the completion of a $49 million round of financing. The syndicate was led by Sofinnova Ventures with participation from additional new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. Existing investors ProChon Holdings BV, Altima Partners, Foun...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.